Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy-induced anemia-Reference-Cited by-同舟云学术

Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy-induced anemia

Published:2016-11-23 Issue:12 Volume:5 Page:3445-3453
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Boccia Ralph V.¹,Henry David H.²,Belton Laura³,Bohac Chet⁴,Ghazal Hassan H.⁵

Affiliation:

1. Center for Cancer and Blood Disorders; Bethesda Maryland

2. University of Pennsylvania; Philadelphia Pennsylvania

3. LB Biostatistics; London United Kingdom

4. Amgen Inc.; Thousand Oaks California

5. Kentucky Cancer Clinic; Hazard Kentucky

Funder

Amgen

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Reference25 articles.

1. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols;Schwartz;Am. J. Health Syst. Pharm.,2007

2. National Comprehensive Cancer Network 2016 NCCN ® Clinical Practice Guidelines in Oncology. Cancer- and Chemotherapy-Induced Anemia version 2 https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf

3. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents;Aapro;Oncologist.,2008

4. Aranesp®

5. Aranesp®

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Erythropoietin combined with traditional Chinese medicine for chemotherapy-induced anemias;Medicine;2020-10-30

2. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC;Journal of Thoracic Oncology;2020-02